Business Context and Reporting Period
Prestige Consumer Healthcare Inc. (PBH) filed this Form 8-K on July 1, 2021, to report material corporate events occurring on that date. The company is a Delaware corporation incorporated in 2012, with principal executive offices in Tarrytown, New York.
Key Financial Metrics and Transactions
- Debt Financing: Entered into Amendment No. 6 to its Term Loan Credit Agreement, creating a new class of Term B-5 Loans with an aggregate principal amount of $600 million.
- Acquisition Cost: Completed the acquisition of the Akorn Consumer Health business assets for a purchase price of $230 million in cash, subject to closing adjustments.
- Interest Rates: The new Term B-5 Loans carry an interest rate of LIBOR plus 2.00% (with a 0.50% floor) or an alternative base rate plus 1.00%.
- Revenue/Profit/Cash Flow: The filing text does not provide specific values for revenue, profit, cash flow, or margins for the reporting period.
Material Changes and Strategic Actions
The primary material change is the completion of the acquisition of the Akorn Consumer Health business, which includes the TheraTears brand and other over-the-counter consumer brands. This transaction was funded through a combination of the new $600 million term loan facility and existing resources. The debt amendment also provides increased flexibility under the credit agreement.
Guidance, Outlook, and Risks
The company intends to use the net proceeds from the new Term B-5 Loans to refinance outstanding term loans, finance the Akorn acquisition, pay associated fees and expenses, and for general corporate purposes. The filing references a press release regarding the acquisition but does not contain specific forward-looking guidance, risk factors, or management commentary beyond the transaction details. The full text of the Asset Purchase Agreement is expected to be filed in the subsequent Form 10-Q.
Investor Verification Checklist
- Verify the final purchase price of the Akorn Consumer Health business after closing adjustments.
- Review the full text of Amendment No. 6 to the Term Loan Credit Agreement (Exhibit 10.1) for covenants and repayment terms.
- Confirm the integration timeline and expected financial contribution of the TheraTears brand in the upcoming 10-Q.
- Assess the impact of the new $600 million debt load on the company's leverage ratios and liquidity position.